Navigation Links
Actavis Launches Generic Keppra XR® Tablets in the U.S.
Date:9/15/2011

MORRISTOWN, N.J., Sept. 15, 2011 /PRNewswire/ -- Actavis, an international generic pharmaceutical company, today announced that it has received FDA approval of Levetiracetam Extended-Release Tablets, a generic equivalent of Keppra XR®.  Shipping commenced immediately following approval.

Keppra XR® had US total sales of approximately $161 million for the 12 months ending June 30, 2011, according to IMS Health.  

About Actavis:

Actavis Inc. is the US distributor of the product and the U.S. subsidiary of Actavis Group hf.  Approximately one third of Actavis Group hf's sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis Inc. has U.S. manufacturing facilities in Elizabeth, NJ and Lincolnton, NC. Actavis also has research and development facilities in Elizabeth, NJ, Owings Mills, MD and Sunrise, FL.

Actavis Group hf is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals.  The company has operations in 40 countries, with more than 10,500 employees.

Keppra XR ® is a trademark owned by a party other than Actavis.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis.  By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.


'/>"/>
SOURCE Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
2. Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII in the U.S.
3. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
4. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
5. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
6. Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S.
7. Actavis Receives Approval of Pantoprazole Sodium Delayed-Release Tablets, USP in the U.S.
8. Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h
9. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
10. Actavis Receives Approval of Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV in the U.S. with 180-Day Marketing Exclusivity
11. Actavis Receives Approval of Losartan Potassium Tablets, USP in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 ... and Healthcare disease pipeline guide Primary Hyperoxaluria - ... the Primary Hyperoxaluria (Genito Urinary System And Sex ... rare condition characterized by recurrent kidney and bladder ... substance called oxalate. Symptoms include blood in the ...
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... oxygen therapy devices market to grow at a CAGR of 10.16% ... Therapy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:3/23/2017)... , March 23, 2017  Additive Orthopaedics, LLC., ... that it has kicked off a multi-centered clinical ... printed bone segments. According to ... variable honeycomb lattice structures have already shown tremendous ... to current allograft wedges from which we have ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 2017 , ... Benefits delivery trailblazer, Hodges-Mace, LLC, ... benefits dashboard solving one of the top frustrations in employee benefits – how ... time, employees can access up-to-date information and account balances for all of their ...
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri ... the greater Fort Collins area, has unveiled a collaboration with nonprofit Big Bones ... Donations to this worthy cause may now be made at http://bigbonescaninerescue.com/ . ...
(Date:3/23/2017)... ... 23, 2017 , ... ChenMed, a privately owned medical, management ... strategic executive team expansion needed to further optimize growth and performance. , “We ... Christopher Chen, MD, ChenMed Chief Executive Officer. “George Wheeler and Donald Trexler ...
(Date:3/23/2017)... ... 23, 2017 , ... Inflow IQ & Inflownomics of Raleigh, NC introduce a ... solid foundation. As experts in dangerous situations the Inflow IQ team can help ... deliver ripe, fresh, clean & refreshing knowledge systems that enhance life. , ...
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... ... Command (USSOCOM) awarded Task Force Dagger Foundation the US Special Operations Command’s Patriot ... During the presentation, General Thomas thanked Task Force Dagger Foundation for its significant ...
Breaking Medicine News(10 mins):